They want to build up the molecules so that they are not subject to the physical phenomenon of entropy, enabling the compound to bind to its target. Taking account of entropy could substantially accelerate the development of the ingredients used in medication. A group led by Nuno Maulide, Head of the Institute for Organic Chemistry at the University of Vienna, will investigate the impact of entropy within the context of the development of active substances in cooperation with the pharmaceutical company Boehinger Ingelheim. The new approach offers great potential for drug development.
Read more about Nuno Maulide, Scientist of the Year 2018.